UBS: Teva raises Copaxone double dose price


According to UBS, Teva Pharmaceuticals has raised the price of the 40-mg dosage of Copaxone by 7.9%.

Despite the criticism of pharmaceutical companies for raising the prices of drugs in the US in 2015, 2016 opened with a series of new price rises. Many pharmaceutical companies raise the price of important drugs at the beginning of the year, and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) is part of the trend.

According to data published by the UBS investment bank, Teva raises its prices for 30 of the drugs it markets by 4%-9.9%. Among other things, the price of 40-mg Copaxone rose 7.9%, while the price of 20-mg Copaxone was not raised.

Copaxone, used to treat multiple sclerosis, is Teva's flagship drug. The 20-mg version of the drug already has generic competition. The double dose, which as a patent-protected drug has no generic competition, accounts for 70% of new Copaxone prescriptions.

UBS Securities analyst Mark Goodman estimated that sales of 40-mg Copaxone totaled $625 million in 2015. Double-dose Copaxone was launched two years ago, and this is the second price hike for the drug, following a similar rise in 2015.

Another of Teva's price hikes was for Azilect, used to treat Parkinson's Disease (9.9%), and in a ProAir HFA inhaler to prevent and treat blockage of the windpipe and in a QVAR inhaler to treat asthma (6% each). Teva raised the prices for Nuvigil and Provigil for treating sleep disorders by 9.8% and 5%, respectively. The price of the Qnasl spray rose by 9.9%, following a 17.1% rise in June 2015.

Published by Globes [online], Israel business news - - on January 10, 2016

© Copyright of Globes Publisher Itonut (1983) Ltd. 2016

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017